American Journal of Ophthalmology
Volume 142, Issue 1 , Pages 1-9 , July 2006

Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration

  • Ziad F. Bashshur, MD

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
    • Corresponding Author InformationInquiries to Ziad Bashshur, MD, American University of Beirut Medical Center, PO Box 11-0236/B11, Beirut, Lebanon
    • ,
  • Ali Bazarbachi, MD

      Affiliations

    • Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    • ,
  • Alexandre Schakal, MD

      Affiliations

    • Department of Ophthalmology, Hotel Dieu de France (St Joseph University), Beirut, Lebanon
    • ,
  • Zeina A. Haddad, MD

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
    • ,
  • Christelle P. El Haibi, MS

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon
    • ,
  • Baha’ N. Noureddin, MD

      Affiliations

    • Department of Ophthalmology, American University of Beirut, Beirut, Lebanon

,Accepted 24 February 2006.

References 

  1. Age-Related Eye Disease Study (AREDS) Research Group . Potential public health impact of Age-Related Eye Disease Study results: AREDS Report No. 11 . Arch Ophthalmol . 2003;121:1621–1624
  2. Eye Diseases Prevalence Research Group . Causes and prevalence of visual impairment among adults in the United States . Arch Ophthalmol . 2004;122:477–485
  3. Eye Diseases Prevalence Research Group . The prevalence of age-related macular degeneration in the United States . Arch Ophthalmol . 2004;122:564–572
  4. Eugene WH , Adamis A . Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration . Can J Ophthalmol . 2005;40:352–368
  5. Wang Y , Fei D , Vanderlaan M , Song A . Biological activity of bevacizumab, a humanized anti-VGEF antibody in vitro . Angiogenesis . 2004;7:335–345
  6. Macular Photocoagulation Study Group . Argon laser photocoagulation for neovascular maculopathy after five years (results from randomized clinical trials) . Arch Ophthalmol . 1991;109:1109–1114
  7. Macular Photocoagulation Study Group . Evaluation of argon green vs. krypton red laser for photocoagulation of subfoveal choroidal neovascularization in Macular Photocoagulation Study . Arch Ophthalmol . 1994;112:1176–1184
  8. Macular Photocoagulation Study Group . Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration (The influence of initial lesion size and visual acuity) . Arch Ophthalmol . 1994;112:480–488
  9. Macular Photocoagulation Study Group . Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration (updated findings from two clinical trials) . Arch Ophthalmol . 1993;111:1200–1209
  10. Miller JW , Schmidt-Erfuth U , Sickenberg M , et al.   Photodynamic therapy for choroidal neovascularization caused by age-related macular degeneration (result of a single treatment in a phase 1 and 2 study) . Arch Ophthalmol . 1999;117:1161–1173
  11. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group . Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials. TAP Report No. 5 . Arch Ophthalmol . 2002;120:1307–1314
  12. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin . Arch Ophthalmol . 1999;117:1329–1345
  13. Gragoudas E , Adamis A , Cunningham E , Feinsod M , Guyer D . Pegaptanib for neovascular age-related macular degeneration . N Engl J Med . 2004;351:2805–2816
  14. Ruckman J , Green LS , Beeson J . 2′ Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165) (inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain) . J Biol Chem . 1998;273:20556–20567
  15. Mulcahy MF , Benson AB . Bevacizumab in the treatment of colorectal cancer . Expert Opin Biol Ther . 2005;5:997–1005
  16. Michels S , Rosenfeld PJ , Puliafito CA , Marcus EN , Venkatraman AS . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration (twelve-week results of an uncontrolled open-label clinical study) . Ophthalmology . 2005;112:1035–1047
  17. Rosenfeld PJ , Moshfeghi AA , Puliafito CA . Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascularization age-related macular degeneration . Ophthalmic Surg Laser Imaging . 2005;36:331–335
  18. United States Pharmacopeia. Proposed revisions to USP chapter 797 Pharmaceutical compounding—Sterile preparations. URL: http://www.usp.org. Access: July 29, 2005.
  19. Rosenfeld P , Schwartz D , Blumenkranz M , Miller J , Haller J , Reimann J , et al.   Maximum tolerated dose of a humanized anti–vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration . Ophthalmology . 2005;112:1048–1053
  20. Fernando NH , Hurwitz HI . Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer . Semin Oncol . 2003;30:S39–S50
  21. Van Wijngaarden P , Coster D , Williams K . Inhibitors of ocular neovascularization promises and potential problems . JAMA . 2005;293:1509–1513
  22. Mordenti J , Cuthbertson RA , Ferrara N , et al.   Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full length and Fab antibodies in rhesus monkeys following intravitreal administration . Toxicol Pathol . 1999;27:536–544
  23. Blaauwgeers HG , Holtkamp GM , Rutten H , et al.   Polarized vascular endothelial growth factor secretion by human retinal pigment endothelium and localization of vascular endothelial growth factor receptor on the inner choriocapillaris. Evidence for a trophic paracrine relation . Am J Pathol . 1999;155:421–428
  24. Mordenti J , Thomsen K , Licko V , et al.   Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation . Toxicol Sci . 1999;52:101–106
  25. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 199;293:865–881.

 See accompanying Editorial on page 141.

PII: S0002-9394(06)00332-1

doi: 10.1016/j.ajo.2006.02.037

American Journal of Ophthalmology
Volume 142, Issue 1 , Pages 1-9 , July 2006

Article Tools

* Image Usage & Resolution